William J Gradishar, Meena S Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H Allison, Sarah L Blair, Harold J Burstein, Chau Dang, Anthony D Elias, Sharon H Giordano, Matthew P Goetz, Lori J Goldstein, Sara A Hurvitz, Steven J Isakoff, Rachel C Jankowitz, Sara H Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Jennifer Matro, Ingrid A Mayer, Joanne Mortimer, Ruth M O'Regan, Sameer A Patel, Lori J Pierce, Hope S Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M Stringer-Reasor, Melinda L Telli, John H Ward, Kari B Wisinski, Jessica S Young, Jennifer L Burns, Rashmi Kumar. J Natl Compr Canc Netw 2021
Times Cited: 90
Times Cited: 90
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin, Henri Roché, Young-Hyuck Im, Ruben G W Quek, Denka Markova, Iulia C Tudor, Alison L Hannah, Wolfgang Eiermann, Joanne L Blum. N Engl J Med 2018
Times Cited: 927
Times Cited: 927
List of shared articles
Times cited
Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer.
Mi Jeong Kwon. Arch Pharm Res 2022
Mi Jeong Kwon. Arch Pharm Res 2022
Chemotherapy Regimens Received by Women With BRCA1/2 Pathogenic Variants for Early Stage Breast Cancer Treatment.
Allison W Kurian, Paul Abrahamse, Ann S Hamilton, Jennifer L Caswell-Jin, Scarlett L Gomez, Timothy J Hofer, Kevin C Ward, Steven J Katz. JNCI Cancer Spectr 2022
Allison W Kurian, Paul Abrahamse, Ann S Hamilton, Jennifer L Caswell-Jin, Scarlett L Gomez, Timothy J Hofer, Kevin C Ward, Steven J Katz. JNCI Cancer Spectr 2022
Systemic Therapy for Hereditary Breast Cancers.
Elizabeth J Harvey-Jones, Christopher J Lord, Andrew N J Tutt. Hematol Oncol Clin North Am 2023
Elizabeth J Harvey-Jones, Christopher J Lord, Andrew N J Tutt. Hematol Oncol Clin North Am 2023
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.
Clifford M Csizmar, Antoine N Saliba, Elizabeth M Swisher, Scott H Kaufmann. Cancers (Basel) 2021
Clifford M Csizmar, Antoine N Saliba, Elizabeth M Swisher, Scott H Kaufmann. Cancers (Basel) 2021
Marker assessments in ER-positive breast cancers: old markers, new applications?
Joshua J X Li, Gary M Tse. Histopathology 2023
Joshua J X Li, Gary M Tse. Histopathology 2023
Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets.
Alberto Zambelli, Riccardo Sgarra, Rita De Sanctis, Elisa Agostinetto, Armando Santoro, Guidalberto Manfioletti. Expert Opin Ther Targets 2022
Alberto Zambelli, Riccardo Sgarra, Rita De Sanctis, Elisa Agostinetto, Armando Santoro, Guidalberto Manfioletti. Expert Opin Ther Targets 2022